Independent Director · RECURSION PHARMACEUTICALS, INC. (RXRX)

Dean Y. Li director compensation at Recursion (FY2025): $291K

Fiscal year 2025 director compensation for Dean Y. Li at RECURSION PHARMACEUTICALS, INC.. Every figure below is printed as the company filed it and cited to the filing it came from.

Director compensation as of the proxy filed April 30, 2026 (DEF 14A). Open the filing on EDGAR.

Free

Get Dean Y. Li’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track Dean Y. Li and every company like it: Velarion Intel, free for 3 days, no card →

What they were paid

RECURSION PHARMACEUTICALS Director Compensation Table · all 2 fiscal years held
In US dollars, as RECURSION PHARMACEUTICALS reports it. Most recent year first. Totals are the company’s disclosed totals.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$41,555$112,502$136,675$0$290,732
FY2024$47,500$112,503$136,727—$296,731

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: RECURSION PHARMACEUTICALS, INC. DEF 14A filed April 30, 2026, accession 0001601830-26-000065, and prior-year filings. Open the filing on EDGAR.

How this page was built: the RECURSION PHARMACEUTICALS, INC. filed document, accession 0001601830-26-000065. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2026.

Get the RECURSION PHARMACEUTICALS Board Governance Report

$290,732 Dean Y. Li, FY2025 total director compensation

$500

The free page is the headline figures. The board report is director pay, board composition and committee fees combined into the same kind of document.

Data as of April 30, 2026 · Source: Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).

How this board is paid

company policy · FY2025

RECURSION PHARMACEUTICALS pays directors a $35,000 cash retainer and $112,500 in equity.

Committees

FY2025 · as the proxy prints them

Research and Development

The rest of the RECURSION PHARMACEUTICALS board

FY2025 · as the company reported each
DirectorRoleFY2025 total
Blake BorgesonIndependent Director$307,149
Christopher GibsonChair of the Board—
Elaine SunIndependent Director$741,570
Franziska MichorIndependent Director$296,136
Najat KhanDirector—
Namandj BumpusIndependent Director$731,605
Robert HershbergLead Independent Director$333,163
Zachary BogueIndependent Director$0
Zavain DarIndependent Director$308,160

The full RECURSION PHARMACEUTICALS compensation record

free company brief

This page is one director within RECURSION PHARMACEUTICALS's record. The company brief lists every named executive and director, each linking to their own page.

Peer companies

named in the RECURSION PHARMACEUTICALS proxy · each links to its own free brief

Order RXRX

Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

Board Governance Report